CRS | CERES Regulatory Services

The Brilinta Resubmission Journey: From FDA CRL to Approval

FDA CRL Wordcloud16

Hello Regulatory Scientists, Today, let’s delve into the journey of Brilinta (ticagrelor) from receiving an FDA Complete Response Letter (CRL) to achieving approval. Understanding this case provides valuable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Brilinta (ticagrelor) Mechanism of Action: P2Y12 receptor antagonist, which inhibits […]

The Farxiga Resubmission Journey: Turning an FDA CRL into Success

FDA CRL Wordcloud11

Hello Regulatory Scientists, Today, let’s explore the journey of Farxiga (dapagliflozin) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case provides invaluable insights and lessons that can guide companies developing new drugs today. Regulatory History and Initial Submission Drug: Farxiga (dapagliflozin) Mechanism of Action: Sodium-glucose co-transporter 2 (SGLT2) inhibitor Indication: Type […]

Turning Setbacks into Success: The Eylea Resubmission Journey

FDA CRL Wordcloud2

Hello Regulatory Scientists, Let’s delve into the journey of Eylea (aflibercept) from receiving an FDA Complete Response Letter (CRL) to its eventual approval. Understanding this case provides valuable insights and lessons for those developing new drugs today. Regulatory History and Initial Submission Drug: Eylea (aflibercept) Mechanism of Action: Vascular Endothelial Growth Factor (VEGF) inhibitor Indication: […]

What to Do After Your First CRL from the FDA: A Story of Turning Setbacks into Success

FDA CRL Wordcloud16

Introduction Imagine you’re a regulatory scientist at a pharmaceutical company. Your team has worked tirelessly for years, conducting clinical trials, collecting data, and finally submitting your New Drug Application (NDA) to the FDA. The anticipation builds as you await their decision, only to receive a Complete Response Letter (CRL). It feels like a punch to […]

The Qsymia Resubmission Journey: Overcoming an FDA Complete Response Letter

FDA CRL Wordcloud14

Hello Regulatory Scientists, Today, let’s explore the journey of Qsymia (phentermine and topiramate extended-release) from receiving an FDA Complete Response Letter (CRL) to gaining approval. This case offers valuable insights and lessons that can be applied by companies developing new drugs today. Regulatory History and Initial Submission Drug: Qsymia (phentermine and topiramate extended-release) Mechanism of […]

Navigating the FDA Complete Response Letter: The Xeljanz Resubmission Journey

FDA CRL Wordcloud5

Hello Regulatory Scientists, Today, let’s dive into the fascinating journey of Xeljanz (tofacitinib) from receiving an FDA Complete Response Letter (CRL) to eventual approval. This case study not only sheds light on the intricacies of regulatory processes but also offers valuable lessons for those developing drugs today. Regulatory History and Initial Submission Drug: Xeljanz (tofacitinib) […]

Surviving an FDA Complete Response Letter: Strategies for Success

FDA CRL Wordcloud3

Dear Regulatory Scientists, Receiving an FDA Complete Response Letter (CRL) after submitting a New Drug Application (NDA) or Biologics License Application (BLA) can feel like a major setback. However, with the right approach, this feedback can be a springboard to ultimate approval. Let’s dive into the immediate actions to take, how to convert a CRL […]

CAR-T Cell Therapy in the FDA Spotlight

1 BKi5QWc zoM2NqpaMl1mhA

CAR-T Cell Therapy in the FDA Spotlight. FDA mandated boxed warnings for CAR-T cell therapies, this followed a 28 November 2023 communication that FDA was “Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies,” and a July — September 2023 Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event […]

Unveiling the Potential of Cell and Gene Therapy in Modern Healthcare

100

  Introduction: In the ever-evolving landscape of healthcare, two essential components take center stage—Drugs and Biologics, with Cell and Gene Therapy at the forefront. These remarkable advancements are not just therapeutic agents; they represent the cutting edge of medical science, offering innovative solutions to a myriad of health challenges. Join us on a journey as […]

The Heartfelt Journey with Advanced Tissue Products

89

Introduction: In the intricate tapestry of healthcare, hope often comes in unexpected forms. Advanced Tissue Products stand as a testament to the compassion and innovation that weave together to redefine the healing journey. Join us on a heartfelt exploration of the profound impact these cutting-edge marvels are having on the lives of individuals, offering not […]